Olipudase alfa
Olipudase alfa is a pharmaceutical drug with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Registry-listed formulations
olipudase alfa · mesh:C000608782
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
3 source entries across 3 studies. This list may not include all unresolved or historical entries.
- GZ402665Registry intervention
Linked study entry; product equivalence not established
View study and source - olipudase alfa (GZ402665)Registry intervention
Linked study entry; product equivalence not established
View study and source - Xenpozyme (olipudase alfa,GZ402665)Registry product
Named ingredient; product remains distinct
Formulation reported by source: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
View study and source
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2/3Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Clinical Trials (7)
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
All 7 trials loaded
Drug Details
- Intervention Type
- Drug
- Molecule Type
- Enzyme
- Total Trials
- 7